Search for: "v. Teva Pharmaceuticals USA, Inc."
Results 121 - 140
of 440
Sort by Relevance
|
Sort by Date
8 Feb 2018, 7:31 am
Teva Pharmaceuticals USA, Inc., February 5, 2018, Stengel, L.). [read post]
2 Feb 2018, 1:31 pm
Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries, Ltd., Case 2016-1284, 2016-1787 (Fed. [read post]
11 Dec 2017, 5:16 pm
The petition of the day is: Teva Pharmaceuticals USA, Inc. v. [read post]
19 Oct 2017, 2:17 pm
TEVA Pharmaceuticals USA, INC. [read post]
19 Oct 2017, 2:17 pm
TEVA Pharmaceuticals USA, INC. [read post]
19 Oct 2017, 10:29 am
In Allergan, Inc. v. [read post]
19 Oct 2017, 10:29 am
In Allergan, Inc. v. [read post]
19 Oct 2017, 7:36 am
Teva Pharmaceuticals USA, Inc. et al, 2-15-cv-01455 (TXED October 16, 2017, Order) (Bryson, CJ) [read post]
16 Oct 2017, 12:36 pm
Teva Pharmaceuticals USA Inc. [read post]
24 Sep 2017, 5:04 pm
Teva Pharmaceuticals USA, Inc. [read post]
29 Aug 2017, 7:35 am
Teva Pharmaceuticals USA, Inc. et al, 2-15-cv-01455 (TXED August 25, 2017, Order) (Bryson, CJ) [read post]
17 Jul 2017, 9:41 am
USA,Inc., 752 F.3d 967, 973 (Fed. [read post]
26 Jun 2017, 7:51 am
Teva Pharmaceuticals USA, Inc., the Federal Circuit panel of Judges Dyk, Mayer and O’Malley determined: “after the AIA, if the existence of the sale is public, the details of the invention need not be publicly disclosed in the terms of sale” for the sale to be invalidating. [read post]
25 Jun 2017, 9:25 pm
District Court for the District of Delaware issued a Memorandum Order that, inter alia, overruled objections by Defendants Glenmark Pharmaceuticals Inc., USA and Teva Pharmaceuticals USA, Inc. to a Report and Recommendation issued by Magistrate Judge Burke and adopted the Report. [read post]
13 Jun 2017, 12:00 pm
Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the “or otherwise available to the public” clause contained in post-AIA 35 U.S.C. [read post]
13 Jun 2017, 12:00 pm
Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the “or otherwise available to the public” clause contained in post-AIA 35 U.S.C. [read post]
8 Jun 2017, 3:27 am
Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the “or otherwise available to the public” clause contained in post-AIA 35 U.S.C. [read post]
28 May 2017, 8:19 pm
Biosig Instruments, Inc. and Teva Pharmaceuticals USA, Inc. v. [read post]
25 May 2017, 6:20 pm
Sandoz, Inc., 749 F. [read post]
4 May 2017, 8:26 am
(“Helsinn”) brought suit against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. [read post]
